Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm

Inclusion Criteria: * Men and women aged above 18 * Subjects who was diagnosed with Essential Blepharospasm * Subjects who voluntarily Signed written informed consent * Subjects who can adhere to protocol and study requirements Exclusion Criteria: * Subjects with known history of allergy considered due to Botulinum toxin type A * Subjects who have received botulinum toxin A type within 3 months * Any disease that might affect neuromuscular function (e.g.. Myasthenia Gravis, Lambert-Eaton Syndrome, Amyotrophic Lateral Sclerosis ect.) * Subjects who are participating in other clinical trials * Pregnant or lactating female Subjects * Subjects who are not eligible for the study at the discretion of the Investigator.